Propanc Biopharma Enters Material Definitive Agreement
Ticker: PPCB · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $175,000, $70,000, $105,000, $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation
TL;DR
Propanc Biopharma just signed a big deal, creating new financial obligations.
AI Summary
On December 3, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement. This agreement also created a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The filing includes financial statements and exhibits related to this event.
Why It Matters
This filing indicates a significant new agreement for Propanc Biopharma, potentially impacting its financial obligations and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks related to performance, funding, and market reception.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- December 3, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Propanc Biopharma, Inc.?
The filing states that Propanc Biopharma, Inc. entered into a material definitive agreement on December 3, 2024, but the specific details of the agreement are not provided in this excerpt.
What type of financial obligation was created by this agreement?
The filing indicates the creation of a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement' for the registrant.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 3, 2024.
What is the principal executive office address of Propanc Biopharma, Inc.?
The principal executive office address of Propanc Biopharma, Inc. is 302, 6 Butler Street, Camberwell, VIC, 3124, Australia.
What is the SEC file number for Propanc Biopharma, Inc.?
The SEC file number for Propanc Biopharma, Inc. is 000-54878.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-06 16:57:01
Key Financial Figures
- $175,000 — ompany an aggregate principal amount of $175,000 AUD. The Company intends to use the net
- $70,000 — at the discretion of the Company), with $70,000 AUD due on February 28, 2024 and $105,0
- $105,000 — 70,000 AUD due on February 28, 2024 and $105,000 AUD due on April 2, 2024. Interest in t
- $15,000 — The Investor also loaned the Company $15,000 to be used for general working capital
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex4-1.htm (EX-4.1) — 1KB
- ex4-1_001.jpg (GRAPHIC) — 3502KB
- 0001493152-24-049110.txt ( ) — 5025KB
- ppcb-20241203.xsd (EX-101.SCH) — 3KB
- ppcb-20241203_lab.xml (EX-101.LAB) — 33KB
- ppcb-20241203_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 6, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer